Polatuzumab Vedotin Enhances Treatment Efficacy in Previously Untreated DLBCL: Insights from the Asia Subpopulation of the POLARIX Trial
In April 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood (IF=25.669). The title of the study is "Polatuzumab…